Eli Lilly COVID-19 antibody combo aces study, cutting hospitalizations and deaths by a whopping 87% CEPI teams up with VBI Vaccines to beat out COVID-19 variants in $33M pact House passes $1.9T COVID-19 package that boosts ACA subsidies, rural hospital funding Johnson & Johnson to sell another 100M coronavirus vaccine doses to U.S., taking America's supply to 800M doses: reports IQVIA doubles down on digital, with 150,000 subjects across 60 trials using its siteless approach In a competitive digital health market, startups move to add new medication delivery services Biopharma roundup—B.1.1.7 variant found to be 30% to 100% more lethal Empatica’s COVID-detecting wearable nets European approval ABIM extends Maintenance of Certification requirement deadlines through 2022 Thermo Fisher plots $600M manufacturing boost to meet COVID demand—and its work won't stop there Agilent names first chief medical officer as it expands diagnostics, genomics businesses J&J CEO Alex Gorsky scores $29.6M in 2020 pay, a $4.2M boost amid hopes for COVID-19 vaccine windfall Grifols ponies up $80M for polyclonal antibody biotech GigaGen Featured Story | By Eric Sagonowsky Lilly’s COVID-19 antibody combo already boasts an FDA authorization for patients at a high risk of developing severe disease, but now it has even stronger data backing the duo. And it's the best data any coronavirus therapy has delivered so far. read more |
| |
|---|
|
Top Stories By Ben Adams The Coalition for Epidemic Preparedness Innovations is funneling $33 million into VBI Vaccines so it can get to work on prepping for new and emerging variants of SARS-CoV-02 that could lessen the efficacy of authorized vaccines. read more By Robert King The House narrowly passed on Wednesday a $1.9 trillion COVID-19 relief package that boosts ACA subsidies and gives more money to rural hospitals, sending the legislation to President Joe Biden for his signature. read more By Eric Sagonowsky One year ago this week, the COVID-19 pandemic hit home with Americans when Tom Hanks revealed he had tested positive and the NBA postponed its season. Things have changed mightily in a year: As a vaccine rollout gains steam, the U.S. is inking yet another huge supply deal—and now has locked down far more doses than it needs to immunize the entire population. read more By Ben Adams This week, we found out IQVIA has been running Johnson & Johnson’s late-stage COVID-19 vaccine test virtually, and, now, the major CRO has outlined just how much it now relies on a decentralized approach. read more By Heather Landi In an increasingly competitive digital health market, many virtual care startups are moving into prescription drug delivery as a key area of growth. Conversely, digital pharmacies are also branching out to add virtual care services as players in the space face competition from Amazon Pharmacy. Here's are the latest moves from some of the major players in the market. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale CDMO Thermo Fisher is making a $600 million capital investment to address COVID demands in the short term and more than double capacity in the long term. Samples of wastewater in Houston indicate that the U.K. variant of COVID-19 is spreading quickly. read more By Conor Hale The makers of a wearable device designed to automatically detect epileptic seizures and call for help have their eyes set on COVID-19—with a newly obtained approval in Europe for a device that detects respiratory infections before symptoms appear. read more By Heather Landi Board-certified physicians are getting another extension on the deadline to maintain their credentials. In light of the COVID-19 pandemic, the American Board of Internal Medicine once again extended the Maintenace of Certification requirements through December 2022. read more By Fraiser Kansteiner Thermo Fisher is laying out more than $600 million in capital investments to more than double its current manufacturing capacity. Through the expansion, the CDMO will add more than 1,500 jobs across North America, Europe and Asia and upgrade its capabilities in bioprocessing, purification and cell culture media. read more By Conor Hale As the lab instrument giant begins to lay down more roads into clinical testing—with recent diagnostics partnerships and cancer testing acquisitions—Agilent Technologies has also named its first chief medical officer to help guide the effort with the appointment of Katharine Knobil. read more By Angus Liu Like many of its Big Pharma peers, Johnson & Johnson suffered some disappointments in its financial results last year, as COVID-19 shutdowns prompted millions of people to put off health care needs unrelated to the virus. But J&J turned the pandemic into an opportunity to speed a vaccine to market—and that benefited CEO Alex Gorsky. read more By Amirah Al Idrus Grifols picked up a 44% stake in GigaGen in 2017 when the duo teamed up to develop polyclonal antibodies under a $50 million pact. Now, the Spanish pharma is dropping $80 million to acquire the remaining 56% of its partner. GigaGen brings with it a pipeline of recombinant polyclonal antibodies in development for primary immune deficiency and infectious diseases such as COVID-19. read more |
